FDA Experts Recommend New Multi-Cancer Blood Test

A group of independent experts has taken a significant step toward the approval of a new medical tool designed to change how we find cancer. On Thursday, an advisory committee for the U.S. Food and Drug Administration (FDA) voted to recommend the Galleri blood test. This test is designed to detect up to 50 different types of cancer from a single blood sample. While the panel agreed that the test is safe and offers clear benefits, the decision came with some hesitation from those involved.

According to MedPage Today, the panel voted in favor of the test’s effectiveness and safety by narrow margins. While the vote on safety was unanimous, the decision on whether the test is truly effective was more difficult. Several experts on the committee expressed concerns about the lack of long-term data. They noted that while the test can find signs of cancer, it is not yet clear if using it leads to better health outcomes for patients in the long run. This is a key point because, in medicine, a test is only considered truly successful if it helps patients live longer or healthier lives.

Dr. Jason Dominitz, a member of the panel from the VA Puget Sound Health Care System, admitted that he struggled with his decision. He explained that while the test can identify cancers, he had not seen enough evidence that this leads to a clear clinical benefit. Similarly, Dr. Stanley Lipkowitz of the National Cancer Institute voted against the test. He argued that because this is a new and "transformative" technology—meaning it could change the way medicine is practiced—the requirements for approval should be very high. He noted that as an oncologist, or a doctor who specializes in cancer, he looks for evidence that a test improves patient survival, which he felt was missing.

Despite these concerns, other panel members felt the test was a major step forward. Dr. Danil Makarov of the NYU School of Medicine supported the test because of its ability to screen for cancers that do not currently have any other detection methods. For many types of cancer, such as thyroid or ovarian cancer, there are no standard tests available to catch the disease early. The ability to find these cancers through a simple blood draw is seen by many as a powerful tool for doctors.

The recommendation follows results from two major studies: PATHFINDER 2 and the NHS-Galleri trial. These studies looked at how well the test could identify cancer signals in the blood. Data from these trials showed that the test has a very high level of accuracy in identifying where a cancer signal comes from in the body. Furthermore, the test showed a low rate of false positives, which are instances where a test incorrectly suggests a person has cancer when they do not. This high accuracy helped convince several panel members to vote in favor of the test.

However, the path forward remains complex. While the NHS-Galleri study showed that the test could detect more early-stage cancers, it did not meet its primary goal of reducing the number of late-stage cancers found across all tumor types. This gap in the data is why some experts remain cautious. They worry that without more information, it is hard to know exactly how the test should be used in a regular clinical setting.

This recommendation is not the final step. The FDA will now review the committee's advice before making a final decision on whether to approve the Galleri test for public use. If approved, it would represent a new way to approach cancer screening, potentially allowing for earlier detection of diseases that are often found too late. For now, the medical community will continue to watch the data closely, balancing the excitement of new technology with the need for proven results that show a clear benefit to patients.